Onyx Pharmaceuticals (ONXX)

Onyx Pharmaceuticals, Inc. (ONXX - Analyst Report) is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborator Bayer Healthcare, the company develops the small molecule drug Nexavar (sorafenib).

Nexavar sales in the third qurater of 2008 remained strong. This is mainly attributed to the market penetration in the liver cancer market, while Nexavar market share in kidney cancer market has stabilized due to heavy competition from Pfizer and Wyeth.

We expect continued Nexavar sales growth in 4Q08 and over the next several years since the label has expanded to liver cancer. In addition to the U.S. and E.U., Nexavar has been approved in South Korea and China for liver cancer. Nexavar has the potential to become a blockbuster. We maintain our Buy rating on Onyx shares with a price target of $45 per shares.

Onyx Pharmaceuticals (ONXX) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BULL OF THE DAY ARCHIVE

Zacks Equity Research: Report For ONXX
N/A	12/14/09
Zacks Blog: Positive Data from Onyx
(ONXX, JNJ, CELG)	12/09/09
Zacks Blog: Onyx Beats Estimates
(ONXX, BAYRY.PK)	11/04/09
Zacks Blog: FDA Approval for GlaxoSmithKline
(GSK, ONXX, PFE)	10/21/09
Zacks Blog: Onyx to Acquire Cancer Drugmaker
(ONXX, CELG)	10/12/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!